Courts Cornelius, Montesinos-Rongen Manuel, Brunn Anna, Bug Stefanie, Siemer Dörte, Hans Volkmar, Blümcke Ingmar, Klapper Wolfram, Schaller Carlo, Wiestler Otmar D, Küppers Ralf, Siebert Reiner, Deckert Martina
Department of Neuropathology, University Hospital of Cologne, Kerpener Strasse 62, Cologne, Germany.
J Neuropathol Exp Neurol. 2008 Jul;67(7):720-7. doi: 10.1097/NEN.0b013e31817dd02d.
Primary lymphomas of the CNS (PCNSLs) show molecular features of the late germinal center exit B-cell phenotype and are impaired in their terminal differentiation as indicated by a lack of immunoglobulin class switching. Because the positive regulatory domain I protein with ZNF domain (PRDM1/BLIMP1) is a master regulator of terminal B-cell differentiation into plasma cells, we investigated a series of 21 PCNSLs for the presence of mutations in the PRDM1 gene and alterations in the expression pattern of the PRDM1 protein. Direct sequencing of all coding exons of the PRDM1 gene identified deleterious mutations associated with abrogation of PRDM1 protein expression in 4 of 21 (19%) PCNSLs. Thus, similar to systemic diffuse large B-cell lymphomas, PRDM1 may be a tumor suppressor in some PCNSL and contribute to lymphomagenesis by impairing terminal differentiation.
中枢神经系统原发性淋巴瘤(PCNSLs)表现出晚期生发中心迁出B细胞表型的分子特征,并且如缺乏免疫球蛋白类别转换所示,其终末分化受损。由于具有锌指结构域的阳性调节域I蛋白(PRDM1/BLIMP1)是B细胞终末分化为浆细胞的主要调节因子,我们研究了一系列21例PCNSLs,以检测PRDM1基因中的突变情况以及PRDM1蛋白表达模式的改变。对PRDM1基因的所有编码外显子进行直接测序,发现在21例(19%)PCNSLs中有4例存在与PRDM1蛋白表达缺失相关的有害突变。因此,与系统性弥漫性大B细胞淋巴瘤相似,PRDM1在某些PCNSL中可能是一种肿瘤抑制因子,并通过损害终末分化促进淋巴瘤的发生。